These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8128425)

  • 1. Standard and method independent units for heparin anticoagulant activities.
    Hemker HC; Béguin S
    Thromb Haemost; 1993 Nov; 70(5):724-8. PubMed ID: 8128425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rational approach to heparins.
    Hemker HC; Béguin S
    Nouv Rev Fr Hematol (1978); 1992; 34(1):5-9. PubMed ID: 1326098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
    Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
    Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity.
    Béguin S; Kessels H; Dol F; Hemker HC
    Thromb Haemost; 1992 Aug; 68(2):136-42. PubMed ID: 1412157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of unfractionated heparin: comparison of materials from the last 50 years.
    Mulloy B; Gray E; Barrowcliffe TW
    Thromb Haemost; 2000 Dec; 84(6):1052-6. PubMed ID: 11154113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin anticoagulant activity: new knowledge and future prospects].
    Camici M; Giusti C; Evangelisti L
    Recenti Prog Med; 1991 Apr; 82(4):209-18. PubMed ID: 1857840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
    Takahashi HK; Nader HB; Dietrich CP
    Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant properties of three mucopolysaccharides used in rheumatology.
    Bauer F; Schulz P; Reber G; Bouvier CA
    Thromb Haemost; 1983 Oct; 50(3):652-5. PubMed ID: 6228031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.